

AMENDMENTS TO THE CLAIMS

1. (original) An adjuvant comprising xenon or a xenon-containing gas .
2. (original) The adjuvant as claimed in claim 1, characterized in that the adjuvant is an adjuvant for hemogenous medicaments or active ingredients.
3. (currently amended) The adjuvant as claimed in claim ~~[[1 or]]~~ 2, characterized in that the adjuvant is gaseous.
4. (currently amended) The adjuvant as claimed in ~~any of claims 1 to~~ claim 3, characterized in that the adjuvant is administered by inhalation.
5. (currently amended) The adjuvant as claimed in ~~any of claims 1 to~~ claim 4, characterized in that xenon is present in a pharmacologically effective amount, in particular in an amount having a subsedative effect, sedative effect, subanalgesic activity, analgesic activity, subhypnotic activity, hypnotic activity, subanesthetic activity or anesthetic activity.
6. (original) A combination medicament which comprises xenon or a xenon-containing gas as adjuvant and at least one additional medicament for simultaneous, separate or sequential use of adjuvant and medicament.
7. (currently amended) The combination medicament as claimed in claim 6, characterized in that the additional medicament comprises at least one ~~of the medicaments:~~ medicament from the group consisting of medicaments with an antiviral, antibacterial, antimycotic, neuroprotective, anticarcinogenic, sedative, analgesically or anesthetically acting substance; opioids; sufentanil, remifentanil; anesthetics, volatile anesthetics; methoxyflurane, halothane, enflurane, isoflurane, sevoflurane and desflurane; local anesthetics; articaine, benzovaine, bupivacaine, butanilicaine, butoxycaine, cinchocaine, cocaine, etidocaine, fomocaine, lidocaine, mepivacaine, oxetacaine, oxybuprocaine, pramocaine, prilocaine, procaine, proxymetacaine, ropivacaine, tolycaine or tetracaine; 2-adrenoceptor agonists, clonidine, dexmedetomidine; catecholamines, parasympathomimetics, parasympatholytics, spasmolytics, sympathomimetics, sympatholytics, β -receptor blocks, tranquilizers, narcoleptics, antidepressants, sedatives, centrally sedative sedating agents, analgesics, antipyretics, migraine remedies, antiparkinson agents, analeptics, antiepileptics, antiemetics, emetics, substances influencing blood clotting, amino acids, vitamins or hormones; medicament s for NOS inhibition, medicaments for treating migraine, medicaments for treating septic shock, medicaments for treating multiple sclerosis, medicaments for treating inflammations or inflammatory pains; hemogenous cerebral medicaments; medicaments for the treatment and/or prophylaxis of stroke, reperfusion

damage, brain trauma, of impairments of blood flow in the brain, of impairment of cerebral perfusion, of cognitive impairments or of postischemia syndrome; barbiturates; barbitol or phenobarbitol, allobarbitol, amobarbitol, aprobarbitol, brallobarbitol, cyclobarbitol, pentobarbitol, proallylanol, secobarbitol and vinylbital, chloral hydrate, methylpentynol, paraldehyde; benzodiazepines, alprazolam, bromazepam, brotizolam, diazepam, flunitrazepam, flurazepam, loprazolam, lormetazepam, midazolam, nitrazepam, oxazepam, temazepam and triazolam; medicaments for neuroprotection, medicaments for the prophylaxis and/or therapy of impairments of cognitive performance; medicaments for Parkinson's disease, Alzheimer's disease, organic brain syndrome, AIDS dementia, depressive pseudodementias, dementing syndromes, deliria as acute organic brain syndromes, intoxications, withdrawal syndromes or cytopathic influences; medicaments for chronic neurodegenerative disorders; m edicaments for Huntington's disease, amyotropically lateral sclerosis, Parkinson's disease, AIDS dementia, Alzheimer's disease or acute neurodegenerative disorders; medicaments for ischemias of the brain or neurotraumata; diagnostic aids, x-ray contrast agents or radioactive isotopes.

8. (original) The use of xenon, of a xenon-containing gas or of a xenon-containing preparation as adjuvant or to produce an adjuvant, in particular as adjuvant or to produce an adjuvant for hemogenous medicaments or for brain-penetrating medicaments or active ingredients.

9. (original) The use as claimed in claim 8, characterized in that the adjuvant is administered with at least one medicament for the treatment of acute and chronic cerebral disorders or impairments or a medicament for the treatment and/or prophylaxis of ischemic brain disorders or the sequelae of a cerebral ischemia or the adjuvant is administered with at least one medicament for the treatment and/or prophylaxis of stroke, reperfusion damage or brain trauma.

10. (new) The adjuvant as claimed in claim 1, characterized in that the adjuvant is gaseous.

11. (new) The adjuvant as claimed in claim 1, characterized in that the adjuvant is administered by inhalation.

12. (new) The adjuvant as claimed in claim 1, characterized in that xenon is present in a pharmacologically effective amount, in particular in an amount having a subsedative effect, sedative effect, subanalgesic activity, analgesic activity, subhypnotic activity, hypnotic activity, subanesthetic activity or anesthetic activity.